SMMT - NASDAQ
Summit Therapeutics Inc.
$15.07
+1.4%Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
At a Glance
Live SnapshotSummit Therapeutics Inc. Profit Bridge
Profitability Analysis
Summit Therapeutics Inc. Income Statement
SMMT • NASDAQ
| Summit Therapeutics Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | Jan 2014 | Jan 2013 | Jan 2012 | Jan 2011 | Jan 2010 | Jan 2009 | Jan 2008 | Jan 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | 704.3K | 1.8M | 860K | 611.9K | 56.4M | 17.5M | 2.9M | 1.3M | 2.3M | 2.3M | 2.9M | 2.8M | 1.2M | 301.9K | 266.6K | 6M | 2M | |
GROSS PROFIT | ||||||||||||||||||||
(0.0) | (15M) | (2.1M) | (2.5M) | (0.0) | (0.0) | (155.4K) | (24.9K) | (97.7K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1M) | (0.0) | (0.0) | (5.8K) | (3.2M) | (596.3K) | |
0.0 | -15M | -2.1M | -1.8M | 1.8M | 860K | 476.6K | 56.4M | 17.4M | 2.9M | 0.0 | 2.3M | 2.3M | 2.9M | 1.8M | 1.2M | 301.9K | 260.9K | 3.5M | 1.4M | |
OPERATING INCOME | ||||||||||||||||||||
(1.1B) | (226M) | (87.7M) | (77.5M) | (88M) | (53.2M) | (39.2M) | (47.7M) | (54.1M) | (33.9M) | (29.4M) | (19.3M) | (8.6M) | (8.5M) | (7.5M) | (5.6M) | (9.5M) | (15.4M) | (26.2M) | (10M) | |
(556.7M) | (60.5M) | (28.2M) | (26.7M) | (23.6M) | (19.2M) | (9.3M) | (17M) | (13.7M) | (9.6M) | (7.5M) | (6.8M) | (3.2M) | (2.7M) | (2.4M) | (2.7M) | (4.2M) | (1.1M) | (2.2M) | (1M) | |
(537.7M) | (150.8M) | (59.5M) | (52.4M) | (85.4M) | (53.3M) | (39.2M) | (51.4M) | (41M) | (23.7M) | (23.9M) | (15.6M) | (6.6M) | (7.5M) | (4.8M) | (3.7M) | (3.7M) | (7.4M) | (15.3M) | (5.8M) | |
-1.1B | -211.3M | -89.7M | -79.3M | -86.2M | -53.2M | -22.6M | 5.4M | -36.6M | -31.1M | -28.7M | -19.2M | -11.1M | -7.2M | -4.7M | -9.4M | -9.2M | -19.2M | -23.4M | -8.6M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (8.7M) | (16.5M) | (4.4M) | (281K) | (255K) | (32.5K) | (620K) | (1.6M) | (1.1M) | (0.0) | (448K) | (0.0) | (0.0) | (4.7K) | (6.3K) | (107K) | (116.7K) | (75.6K) | (11.8K) | |
0.0 | 4.8M | -6.1M | -2.9M | -242K | -251K | -36.2K | -615K | 2.7M | -1.1M | 30K | -448K | 14.8K | 17.4K | 6.3K | 20.6K | -94.3K | 314.2K | 1.5M | 1.7M | |
(0.0) | (14.7M) | (0.0) | -1.6M | -21M | -13.5M | -18.8M | -14.4M | -743K | (640K) | -3.1M | -683K | -683K | (19K) | (339.2K) | (6.9M) | (3.5M) | (11M) | (8.7M) | (3.2M) | |
14.8M | 4.7M | -526.1M | -4M | -2.4M | 206.9K | -10.2M | 3.7M | 1.9M | -1.1M | -2.8M | -427K | 9K | 11K | 4K | 20.6K | -94.3K | 314.2K | 1.5M | 1.7M | |
-1.1B | -221.3M | -615.9M | -83.3M | -88.6M | -52.9M | -28.4M | 9.1M | -33.9M | -32.1M | -23.2M | -12.7M | -11.1M | -7.2M | -4.7M | -9.4M | -9.3M | -18.9M | -21.9M | -6.9M | |
NET INCOME | ||||||||||||||||||||
(0.0) | (0.0) | -946K | -4.5M | -15.2M | -213K | -4.5M | -1.8M | -5.3M | -5.4M | -4.4M | -2M | -1M | -539K | -477K | -1.9M | -594K | -2.5M | -1.8M | -959K | |
-1.1B | -221.3M | -614.9M | -78.8M | -88.6M | -52.7M | -23.9M | 9.9M | -28.5M | -21.4M | -24.3M | -17.1M | -10.1M | -6.7M | -4.2M | -7.4M | -8.7M | -32.3M | -20.1M | -5.9M |
SEC Filings
SMMT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | June 01, 2026 | May 30, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | April 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 07, 2025 | November 07, 2025 | 2025 |
Related Guides
Continue your SMMT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.